JP2024539273A - Mage-a4抗原を標的とするペプチドおよび操作されたt細胞受容体ならびに使用の方法 - Google Patents

Mage-a4抗原を標的とするペプチドおよび操作されたt細胞受容体ならびに使用の方法 Download PDF

Info

Publication number
JP2024539273A
JP2024539273A JP2024524598A JP2024524598A JP2024539273A JP 2024539273 A JP2024539273 A JP 2024539273A JP 2024524598 A JP2024524598 A JP 2024524598A JP 2024524598 A JP2024524598 A JP 2024524598A JP 2024539273 A JP2024539273 A JP 2024539273A
Authority
JP
Japan
Prior art keywords
tcr
polypeptide
cells
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539273A5 (cg-RX-API-DMAC7.html
Inventor
カシアン イー
ケ パン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2024539273A publication Critical patent/JP2024539273A/ja
Publication of JP2024539273A5 publication Critical patent/JP2024539273A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024524598A 2021-10-25 2022-10-24 Mage-a4抗原を標的とするペプチドおよび操作されたt細胞受容体ならびに使用の方法 Pending JP2024539273A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163271368P 2021-10-25 2021-10-25
US63/271,368 2021-10-25
US202163279527P 2021-11-15 2021-11-15
US63/279,527 2021-11-15
PCT/US2022/078597 WO2023076863A2 (en) 2021-10-25 2022-10-24 Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use

Publications (2)

Publication Number Publication Date
JP2024539273A true JP2024539273A (ja) 2024-10-28
JP2024539273A5 JP2024539273A5 (cg-RX-API-DMAC7.html) 2025-10-31

Family

ID=86158936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524598A Pending JP2024539273A (ja) 2021-10-25 2022-10-24 Mage-a4抗原を標的とするペプチドおよび操作されたt細胞受容体ならびに使用の方法

Country Status (5)

Country Link
US (1) US20260125448A1 (cg-RX-API-DMAC7.html)
EP (1) EP4422651A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024539273A (cg-RX-API-DMAC7.html)
CA (1) CA3236237A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023076863A2 (cg-RX-API-DMAC7.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX395611B (es) * 2016-04-08 2025-03-25 Adaptimmune Ltd Receptores de celulas t.
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
AU2018395397A1 (en) * 2017-12-28 2020-08-06 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
MX2021015946A (es) * 2019-06-18 2022-04-18 Regeneron Pharma Receptores de linfocitos t de mage-a4 y métodos de uso de estos.
EP4153618A4 (en) * 2020-05-18 2024-06-26 Board of Regents, The University of Texas System MANIPULATED T-CELL RECEPTORS AND METHODS OF USE

Also Published As

Publication number Publication date
WO2023076863A3 (en) 2023-06-15
US20260125448A1 (en) 2026-05-07
CA3236237A1 (en) 2023-05-04
WO2023076863A2 (en) 2023-05-04
EP4422651A2 (en) 2024-09-04
EP4422651A4 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
JP7785696B2 (ja) 操作されたt細胞受容体および使用の方法
EP4610654A2 (en) Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2
JP2024539291A (ja) 神経膠芽腫を治療するための方法および組成物
JP2023548556A (ja) Egfr抗原を標的とする操作されたt細胞受容体および使用方法
TWI893070B (zh) 經工程化之t細胞受體及使用方法
JP7827645B2 (ja) 操作されたt細胞受容体および使用の方法
US20260125448A1 (en) Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
US20260007698A1 (en) Peptides and engineered t cell receptors targeting vcy antigen and methods of use
US20250289866A1 (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
US20250073333A1 (en) Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
WO2025096983A1 (en) Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
WO2025101705A1 (en) Peptides and engineered t cell receptors targeting a melanoma antigen preferentially expressed in tumors antigen and methods of use
WO2026019786A1 (en) Peptides and engineered t cell receptors targeting brachyury antigen and methods of use
CN118302176A (zh) 靶向mage-a4抗原的肽和经改造t细胞受体及使用方法
CN117425482A (zh) 靶向egfr抗原的经改造t细胞受体和使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251023

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260723